After a PhD in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.

She then joined Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area. She completed an Executive MBA in 2003 and had worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the Biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg) in 2012. She is an author of 87 publications and filed 13 patents.

She served in standardisation committees on Cardiovascular Biomarkers at AACC and IFCC for 15 years; she also created and chaired the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She is punctually serving as an expert for the European Commission (H2020, IMI, PerMed programmes) and for the Luxembourg Plan Cancer.